**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 63979

**Manuscript Type:** ORIGINAL ARTICLE

***Case Control Study***

**Altered profiles of fecal bile acids correlate with gut microbiota and inflammatory responses in patients with ulcerative colitis**

Yang ZH *et al*. Altered fecal bile acids in UC

Zhen-Huan Yang, Fang Liu, Xiao-Ran Zhu, Fei-Ya Suo, Zi-jun Jia, Shu-Kun Yao

**Zhen-Huan Yang, Xiao-Ran Zhu, Fei-Ya Suo, Zi-jun Jia,** Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China

**Zhen-Huan Yang, Fang Liu, Xiao-Ran Zhu, Fei-Ya Suo, Shu-Kun Yao,** Department of Gastroenterology, China-Japan Friendship Hospital, Beijing 100029, China

**Author contributions:** Yang ZH designed and performed the study, analyzed the data, and drafted the manuscript; Liu F and Jia ZJ collected the samples and clinical data of the patients; Zhu XR and Suo FY took part in designing the study and analyzing the data; Yao SK designed the study, supervised the study performance, revised the manuscript, and obtained the funding.

**Supported by** National Key Technology Support Program during “12th Five-Year Plan” Period of China, No. 2014BAI08B00; National Key Research and Development Plan for Precision Medicine Research, No. 2017YFC0910002; and Leap-forward Development Program for Beijing Biopharmaceutical Industry (G20), No. Z171100001717008.

**Corresponding author: Shu-Kun Yao, MD, Professor,** Department of Gastroenterology, China-Japan Friendship Hospital, No. 2 Yinghua East Street, Chaoyang District, Beijing 100029, China. shukunyao@126.com

**Received:** February 6, 2021

**Revised:** March 22, 2021

**Accepted:** May 25, 2021

**Published online:** June 28, 2021

**Abstract**

BACKGROUND

Gut microbiota and its metabolites may be involved in the pathogenesis of inflammatory bowel disease. Several clinical studies have recently shown that patients with ulcerative colitis (UC) have altered profiles of fecal bile acids (BAs). It was observed that BA receptors Takeda G-protein-coupled receptor 5 (TGR5) and vitamin D receptor (VDR) participate in intestinal inflammatory responses by regulating NF-ĸB signaling. We hypothesized that altered profiles of fecal BAs might be correlated with gut microbiota and inflammatory responses in patients with UC.

AIM

To investigate the changes in fecal BAs and analyze the relationship of BAs with gut microbiota and inflammation in patients with UC.

METHODS

The present study used 16S rDNA sequencing technology to detect the differences in the intestinal flora between UC patients and healthy controls (HCs). Fecal BAs were measured by targeted metabolomics approaches. Mucosal TGR5 and VDR expression was analyzed using immunohistochemistry, and serum inflammatory cytokine levels were detected by ELISA.

RESULTS

Thirty-two UC patients and twenty-three HCs were enrolled in this study. It was found that the diversity of gut microbiota in UC patients was reduced compared with that in HCs. *Firmicutes*, *Clostridium IV*, *Butyricicoccus*, *Clostridium XlVa*, *Faecalibacterium*, and *Roseburia* were significantly decreased in patients with UC (*P* = 3.75E-05, *P* = 8.28E-07, *P* = 0.0002, *P* = 0.003, *P* = 0.0003,and *P* = 0.0004, respectively). *Proteobacteria*, *Escherichia*, *Enterococcus*, *Klebsiella*, and *Streptococcus* were significantly enriched in the UC group (*P* = 2.99E-09, *P* = 3.63E-05, *P* = 8.59E-05, *P =* 0.003, and *P* = 0.016, respectively). The concentrations of fecal secondary BAs, such as lithocholic acid, deoxycholic acid, glycodeoxycholic acid, glycolithocholic acid, and taurolithocholate, in UC patients were significantly lower than those in HCs (*P* = 8.1E−08, *P* = 1.2E−07, *P* = 3.5E−04, *P* = 1.9E−03,and *P* = 1.8E−02, respectively) and were positively correlated with *Butyricicoccus*, *Roseburia*, *Clostridium IV*, *Faecalibacterium*, and *Clostridium XlVb* (*P* < 0.01). The concentrations of primary BAs, such as taurocholic acid, cholic acid, taurochenodeoxycholate, and glycochenodeoxycholate, in UC patients were significantly higher than those in HCs (*P* = 5.3E−03, *P* = 4E−02, *P* = 0.042, and *P* = 0.045, respectively) and were positively related to *Enterococcus*, *Klebsiella*, *Streptococcus*, *Lactobacillus,* and pro-inflammatory cytokines (*P* < 0.01). The expression of TGR5 was significantly elevated in UC patients (0.019 ± 0.013 *vs* 0.006 ± 0.003, *P =* 0.0003). VDR expression in colonic mucosal specimens was significantly decreased in UC patients (0.011 ± 0.007 *vs* 0.016 ± 0.004, *P* = 0.033).

CONCLUSION

Fecal BA profiles are closely related to the gut microbiota and serum inflammatory cytokines. Dysregulation of the gut microbiota and altered constitution of fecal BAs may participate in regulating inflammatory responses *via* the BA receptors TGR5 and VDR.

**Key Words:** Ulcerative colitis; Gut microbiota; Bile acids; Takeda G-protein-coupled receptor 5; Vitamin D receptor

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Yang ZH, Liu F, Zhu XR, Suo FY, Jia ZJ, Yao SK. Altered profiles of fecal bile acids correlate with gut microbiota and inflammatory responses in patients with ulcerative colitis. *World J Gastroenterol* 2021; 27(24): 3609-3629

**URL:** https://www.wjgnet.com/1007-9327/full/v27/i24/3609.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v27.i24. 3609

**Core Tip:** This study comprehensively investigated the changes in gut microbiota and fecal bile acid profiles and analyzed the relationship of bile acids with gut microbiota and inflammation in patients with ulcerative colitis. It was demonstrated that fecal bile acid profiles are closely related to gut microbiota and serum inflammatory cytokines. Dysregulation of gut microbiota and altered constitution of fecal bile acids may participate in regulating inflammatory responses *via* the bile acid receptors Takeda G-protein-coupled receptor 5 and vitamin D receptor.

**INTRODUCTION**

Ulcerative colitis (UC) is a form of inflammatory bowel disease (IBD). It is characterized by continuous and diffuse inflammation starting in the rectum that can extend to proximal segments of the colon. The typical symptoms of UC include bloody diarrhea, abdominal pain, fecal urgency, and tenesmus. According to relevant epidemiological studies, the prevalence rates are high in Western developed countries, particularly in Europe (505 per 100000 in Norway) and North America (286 per 100000 in the United States)[1]. With the popularization of colonoscopy screening and changes in lifestyle and diet, the incidence and prevalence of UC have been increasing over time worldwide[2].

The natural history of UC includes periods of remission and flare-ups, and the goal of therapy is to induce and maintain clinical remission free of corticosteroids, thus minimizing the impact on quality of life[3]. Currently, treatments for UC include 5-aminosalicylates[4], corticosteroids[5], antitumor necrosis factor alpha drugs[6], antibiotics[7], probiotics[8], and immunosuppressants[9]. Studies indicate that a substantial proportion of patients who fail to respond to mesalamine for remission induction often rely on corticosteroids and/or immunomodulators to control the disease[10]. Corticosteroid resistance/refractoriness rates range from 8.9% to 25% in individuals with IBD[11,12]. Patients with long-standing IBD involving at least 1/3 of the colon are at an increased risk for colorectal cancer [13]. Colectomy is needed in up to 15% of patients with UC[14]. Therefore, it is necessary to explore the pathogenesis of UC, and effective therapies that can induce and maintain remission in UC without serious side effects are forthcoming.

The etiology and pathogenesis of IBD are still unclear. It is generally believed that various factors, such as the environment, genetics, immunity, and intestinal microbes, play a key role in the occurrence and development of IBD[15]. The human gut microbiota is a dynamic and diverse community of commensal bacteria, fungi, and viruses; among them, bacteria, of which there are over 1000 different species, constitute the majority[16,17]. Microorganisms regulate multiple aspects of host functions, including fermentation of dietary fibers[18], pathogen defense[19], metabolism, and immune maturation[20]. Multiple studies have indicated differences in the composition of the gut microbiota in UC, including reduction in diversity, decreased abundances of bacterial taxa within the *Firmicutes* and *Bacteroides*, and increases in the members of the *Proteobacteria* *phylum*, such as *Enterobacteriaceae*[21-23].

One of the primary modes by which the gut microbiota interacts with the host is by means of metabolites. Bile acid (BA) metabolites have recently drawn much attention in UC. BAs can be divided into two categories based on structure: Free BAs, including cholic acid (CA), chenodeoxycholic acid (CDCA), deoxycholic acid (DCA), and lithochalic acid (LCA); and conjugated BAs, which are a combination of the abovementioned free BAs and glycine or taurine. BAs can also be divided into primary BAs and secondary BAs based on the source. The intestinal microbiota converts the primary BAs synthesized by host cells to secondary BAs. A few clinical studies have shown that there is a disorder of BA metabolism in patients with UC, which is characterized by enrichment of primary BAs and conjugated BAs and reduction of secondary BAs such as LCA and DCA[24-26]. Nevertheless, previous studies have only measured various fecal BAs but have not extensively investigated their relationships with the gut microbiota, its metabolites, and inflammatory cytokines in patients with UC.

BA receptors mediate the effects of BAs in the intestine, including nuclear receptors and membrane receptors. Nuclear receptors include farnesoid X receptor (FXR), pregnane X receptor, and vitamin D receptor (VDR). Membrane receptor refers to G protein-coupled bile acid receptor 1, also known as Takeda G protein-coupled receptor 5 (TGR5)[27,28]. The TGR5 and VDR signaling pathways play an important role in regulating inflammatory responses, cell proliferation, and apoptosis and controlling glycolipid and energy metabolism. Animal studies have shown that TGR5 and VDR participate in intestinal immune regulation and barrier function and reduce inflammatory responses[29]. However, the expression of the BA receptors VDR and TGR5 in colonic mucosal specimens from UC patients is still unclear.

Therefore, we hypothesized that dysregulation of the gut microbiota and altered constitution of fecal BAs may participate in regulating inflammatory responses *via* the BA receptors TGR5 and VDR. This study focused on the changes in the gut microbiota, fecal BA profiles, and BA receptor expression in the colonic mucosa. Correlations between these parameters were also analyzed. The findings may provide new insights into the pathogenesis of UC and the development of effective therapeutic methods for UC.

**MATERIALS AND METHODS**

***Recruitment of subjects and sample collection***

Based on the sample size of other studies[26,30-32], a total of 32 UC patients and 23 age- and sex-matched healthy controls (HCs) were recruited in the study. All patients were treated at the gastroenterological department of China-Japan Friendship Hospital from April 2019 to January 2020. Ulcerative colitis usually presents with bloody diarrhea and is diagnosed by colonoscopy and histological findings, as well as the exclusion of infectious and noninfectious colitis. The Mayo score of disease activity of the enrolled patients was required to be 4-12 to ensure that the clinical symptoms were significant at the study entry.

The exclusion criteria for UC patients were as follows: (1) Below the age of 18 or above the age of 65 years; (2) use of probiotics or prokinetics, antispasmodics, and analgesics within 2 wk, or antibiotics, corticosteroids, immunosuppressants, BA sequestrants, and lipid-lowering agents within 3 mo; (3) previous major abdominal surgery or organic diseases such as celiac disease; (4) severe hypertension, diabetes, coronary heart disease, psychiatric disorders, or biliary or liver comorbidities; (5) pregnancy, lactation, or planned pregnancy; and (6) uncooperativeness. All subjects gave written informed consent before participation. The study protocol was approved by the Ethics Committee of the China-Japan Friendship Hospital (No. 2019-K16).

After enrollment, the clinical status of each subject was first assessed using validated questionnaires. Fasting blood specimens were collected from all subjects, and serum samples were obtained and stored at -80 °C until analysis. Stool samples were collected as soon as possible within 1 d of UC patients' visit to prevent initiation of medical treatment from changing the composition of the intestinal flora. The pharmacological agents aforementioned were not allowed throughout the study period. Each fecal sample was divided into two parts with sterile plastic tubes after defecation. Samples were frozen in liquid nitrogen immediately and stored at -80 °C. All subjects were required to maintain their daily dietary habits at least 1 wk before the collection of the stool samples and until all of the assessments were finished. The next day, subjects underwent colonoscopy after standard bowel preparation with polyethylene glycol electrolyte solution, and one mucosal pinch biopsy was taken from the colorectal lesion. The specimen was immediately fixed in 10% formalin for at least 72 h, embedded in paraffin, and sectioned (4 μm) for immunohistochemistry.

***Clinical assessments***

Clinical assessments were first conducted using standardized questionnaires. The severity indexes of UC were assessed using the previously validated Mayo score[33]. The scoring system determines the severity of UC based on the patient’s bloody diarrhea, doctor’s assessment, and colonoscopy. Montreal classification was used to assess the extent of UC[34]. The Bristol Stool Form Scale (BSFS), a 7-point scale, was used to measure stool form.

***DNA extraction, 16S rDNA amplification, and Illumina sequencing***

Total DNA extraction was performed according to the instructions of the E.Z.N.A. soil kit (Omega Biotek, Norcross, GA, United States). The DNA concentration and purity were determined using a Thermo NanoDrop2000, and the quality of DNA extraction was validated by 1% agarose gel electrophoresis; 341F (5′-CCTACGGGRSGCAGCAG-3′) and 806R (5′-GGACTACVVGGGTATCTAATC-3′) primers were used for PCR amplification of the V3-V4 variable region using the following amplification procedure: Predenaturation at 95 °C for 3 min, amplification for 27 cycles (denaturation at 95 °C for 30 s, annealing at 55 °C for 30 s, and extension at 72 °C for 30 s), and final extension at 72 °C for 10 min (PCR instrument: ABI GeneAmp 9700). The 20 μL reaction mixture included 4 μL of 5 ×FastPfu buffer, 2 μL of 2.5 mmol/L dNTPs, 0.8 μL of primer (5 μmol/L), 0.4 μL of FastPfu polymerase, and 10 ng of DNA template.

The PCR products were recovered using a 2% agarose gel, purified with an AxyPrep DNA Gel Extraction Kit (Axygen Biosciences, Union City, CA, United States), eluted with Tris-HCl, and detected by 2% agarose electrophoresis. Quantification was performed using QuantiFluor-ST (Promega, United States). Sequencing was performed using Illumina’s MiSeq PE250 platform (Illumina, San Diego, United States).

***Bile acid quantitation***

BAs in feces were measured according to previously reported methods[35,36]. A Waters ACQUITY ultra-performance LC system coupled with a Waters XEVO TQ-S mass spectrometer with an ESI source controlled by MassLynx 4.1 software (Waters, Milford, MA) was used for all analyses. Chromatographic separations were performed with an ACQUITY BEH C18 column (1.7 μm, 100 mm × 2.1 mm internal dimensions; Waters, Milford, MA). UPLC-MS raw data obtained in negative mode were analyzed using TargetLynx Applications Manager version 4.1 (Waters Corp., Milford, MA) to obtain calibration equations and the concentration of each BA in the samples.

***Immunohistochemistry***

Paraffin sections were processed for immunohistochemistry. Following deparaffinization, antigen repair, endogenous peroxidase inhibition, and nonspecific antigen blocking, the sections were incubated with primary antibodies (rabbit monoclonal anti-TGR5 antibody, 1:100; rabbit monoclonal anti-VDR antibody, 1:100; Abcam, Cambridge, United Kingdom) overnight at 4 °C. Following thorough washing with PBS, slides were incubated at room temperature for 1 h with horseradish peroxidase-conjugated anti-mouse rabbit secondary antibody (Zhongshan Gold Bridge, Beijing, China) and then visualized using diaminobenzidine. Finally, slides were counterstained with hematoxylin and viewed under a light microscope.

For each section, five nonoverlapping fields at 400 × magnification were randomly selected and scanned under an OLYMPUS microscope. Images were analyzed with Image-Pro Plus 6.0 software (Media Cybernetics, Bethesda, MD, United States). The mean optical density of the mucosal staining area was used to measure the expression of TGR5 and VDR. All sections were inspected independently by two blinded observers, and the mean values of the readings were used for final analysis.

***Statistical analysis***

Statistical analyses were performed using SPSS software, version 24.0 (SPSS Inc, Chicago, IL, United States). The normality of the distribution of the variables was tested using the Shapiro-Wilk test. Normally distributed data are presented as the mean ± SD, and abnormally distributed data are expressed as the median [interquartile range (IQR)]. Comparisons between groups were performed using independent sample *t*-tests for normally distributed data with homogeneous variances or nonparametric Mann-Whitney *U* tests. The χ2 test or Fisher’s exact test was used to analyze qualitative data. Correlations between BA metabolites and other parameters were explored using Pearson’s correlation analysis for normally distributed data or Spearman’s correlation analysis for nonnormally distributed data or ranked data. *P*-values were two-sided, and differences were considered significant at *P* <0.05. Statistical charts were generated with GraphPad Prism 5.0 software (GraphPad Software Inc, La Jolla, CA, United States).

**RESULTS**

***Characteristics of study subjects***

The demographics and clinical characteristics of UC patients and HCs are presented in Table 1. Thirty-two UC patients (17 males and 15 females; median age 37.0 years, IQR: 32.00-49.75) and twenty-three HCs (13 males and 10 females; median age 32.0 years, IQR: 27.00-51.00) were enrolled in this study. There were no significant differences between the groups in age (*P* = 0.570), sex (*P* = 0.803), or body mass index (*P* = 0.337). In UC patients, the duration of disease ranged from 0.5 to 25 years (median 2 years). According to the Mayo scores (7.8 ± 1.9), 5 (15.6%) patients had mild UC, and 25 (78.1%) had moderate UC. The BSFS score [UC: 6.0 (6.0, 6.0) *vs* HC: 4.0 (4.0, 4.0)] was significantly higher in UC patients than in HCs.

***Structural characteristics of gut microbiota in the UC and control groups***

Among the 594 operational taxonomic units (OTUs) detected, a total of 317 OTUs were identified in the two groups, including 86 unique OTUs in the UC group and 191 unique OTUs in the control group (Figure 1A). The dilution curve analysis based on the Sobs index for community richness and the Shannon index for community diversity showed that the sequencing volume covered all the microorganisms in the samples and met the data analysis requirements (Figure 1B). The species accumulation curve based on whether the sample size is sufficient and the estimated species richness showed that the sequencing sample size was sufficient, which can reflect most of the microbial information in the sample (Figure 1C). Principal coordinate analysis was performed to assess the similarity of the bacterial communities, which clearly differentiated the intestinal flora of the UC group from the control group (Figures 1D). Chao community richness index or the Shannon and Simpson community alpha diversity indexes of the UC group were significantly lower than those of the control group, indicating that the diversity of flora was reduced (Figure 1E). The community compositions of the intestinal microbes in the UC group and control group were analyzed at the phylum and genus levels. At the phylum level, the dominant phyla found in both groups were *Firmicutes*, *Bacteroidetes*, *Proteobacteria*, and *Actinobacteria* (the proportions in the two groups were 46.06%, 28.69%, 20.60%, and 3.61% *vs* 68.75%, 26.32%, 2.28%, and 1.66%, respectively), while at the genus level, *Bacteroides*, *Faecalibacterium*, *Escherichia*, *Prevotella*, and *Roseburia* were the top five genera (the proportions of which were 24.64%, 10.88%, 15.03%, 6.50, and 4.96% *vs* 21.05%, 24.59%, 0.63%, 7.12% and 8.32%, respectively) (Figure 1F).

***Screening of different key gut microbiota between the UC and control groups***

The Wilcoxon rank sum test of differential species between the two groups showed significant changes in the intestinal microbes between the UC and control groups (Figure 2A). At the phylum level, *Firmicutes* and *Proteobacteria* in the UC group were significantly different from those in the control group (*P* = 3.75 × 105, *P* = 2.99 × 109). At the genus level, the percentages of *Clostridium IV*, *Butyricicoccus*, *Clostridium XlVa*, *Faecalibacterium*, *Roseburia*, and *Coprococcus* in the UC group were significantly lower than those in the control group (*P* = 8.28 × 107, *P* = 0.0002, *P* = 0.003, *P* = 0.0003, *P* = 0.0004, and *P* = 7.38 × 106, respectively), and the percentages of *Escherichia*, *Enterococcus*, *Klebsiella*, and *Streptococcus* were significantly higher than those in the control group (*P* = 3.63 × 105, *P* = 8.59 × 105, *P =* 0.003, and *P* = 0.016, respectively). LEfSe analysis identified (threshold 2) the differential intestinal microbial communities between the two groups (Figure 2B). *Clostridia*, *Clostridiales*, *Firmicutes*, *Ruminococcaceae*, and *Faecalibacterium* were significantly enriched in the control group. *Proteobacteria*, *Gammaproteobacteria*, *Enterobacteriaceae*, *Enterobacteriales*,and *Escherichia\_Shigella* were significantly enriched in the UC group.

***Analysis of difference in fecal BAs between the UC and control groups***

PCA was performed to evaluate the similarity of the fecal BAs of the two groups. Twenty-four BAs clearly distinguished the UC group from the control group (Figure 3). Fecal secondary BAs were significantly decreased in UC patients compared with healthy controls (Figure 3B). The concentrations of fecal secondary BAs such as LCA, DCA, 12\_ketoLCA, glycol-deoxycholic acid (GDCA), glycol-lithocholic acid (GLCA), and tauro-lithocholic acid (TLCA) were significantly lower than those in healthy controls (*P* = 8.1 × 108, *P* = 1.2 × 107, *P* = 6.3 × 107, *P* = 3.5 × 104, *P* = 1.9 × 103, and *P* = 1.8 × 102, respectively) (Figure 3C-H). The concentrations of primary BAs such as taurocholic acid (TCA), CA, tauro-chenodeoxycholic acid (TCDCA), and glycol-chenodeoxycholic acid (GCDCA) were significantly higher than those in HCs (*P* = 5.3 × 103, *P* = 4 × 102, *P* = 0.042, and *P* = 0.045, respectively) (Figure 3I and M). The concentrations of CDCA and glycol-cholic acid (GCA) showed a tendency to increase in UC patients but failed to reach a significant level (*P* = 0.138 and *P* = 0.074, respectively) (Figure 3J and N).

***Correlations between fecal BAs and intestinal microbes* *in all subjects***

Correlative assessments were made on the fecal BAs and intestinal microbes (Figure 4). The results showed that DCA, LCA, and 12\_ketoLCA were negatively correlated with *Enterococcus*, *Klebsiella*, *Streptococcus*, and *Lactobacillus*. CA, CDCA, TCA, TCDCA, GCA, and GCDCA were positively related with *Enterococcus*, *Klebsiella*, *Streptococcus*, and *Lactobacillus*. *Butyricicoccus*, *Roseburia*, *Clostridium IV*, *Faecalibacterium*, *Ruminococcus*, *Clostridium XlVb*, *Coprococcus,* and *Alistipes* were negatively correlated with the concentrations of CA, CDCA, TCA, TCDCA, GCA, and GCDCA and positively correlated with the concentrations of DCA, LCA, 12\_ketoLCA, GLCA, and GDCA.

***Mucosal immunohistochemistry***

Representative photomicrographs of the immunoreactivity of TGR5 and VDR in the mucosa of UC patients and HCs are shown in Figure 5A-D (× 400 magnification). The level of TGR5 in mucosal biopsies was significantly higher in UC patients than in HCs (0.019 ± 0.013 *vs* 0.006 ± 0.003, *P=*0.0003) (Figure 5E). VDR expression in colonic mucosal specimens decreased significantly in UC patients (0.011 ± 0.007 *vs* 0.016 ± 0.004, *P* = 0.033) (Figure 5F).

***Serum inflammatory cytokine levels and correlations between fecal BAs and serum inflammatory cytokines***

The levels of inflammatory cytokines in the serum of UC patients and HCs were quantified by ELISA. The levels of IL-1α, IL-1β, TNF-α, IL-2, and IL-6 were significantly higher in UC patients (*P* < 0.0001) (Figure 6A-E). TCA, GCA, and GCDCA were positively correlated with IL-1α (*P <* 0.05); TCA and TNF-α were positively correlated (*P <* 0.05); LCA, DCA, 12-KetoLCA, TLCA, GDCA, and 6-Keto-LCA were negatively correlated with the levels of IL-1α, IL-1β, TNF-α, and IL-6 (*P <* 0.01) (Figure 6F and G).

**DISCUSSION**

This study comprehensively investigated the changes in fecal BA profiles and analyzed the associations of BAs with the gut microbiota and inflammation in patients with UC. As expected, these data confirmed the differences in fecal BA compositions between UC patients and HCs, and the concentrations of some BAs were significantly correlated with the gut microbiota and serum inflammatory cytokines. Specifically, the concentrations of fecal secondary BAs such as LCA, DCA, GDCA, GLCA, and TLCA in UC patients were significantly lower than those in HCs and were positively correlated with *Butyricicoccus, Roseburia, Clostridium IV, Faecalibacterium,* and *Clostridium XlVb*. The concentrations of primary BAs such as TCA, CA, TCDCA, and GCDCA in UC patients were significantly higher than those in HCs and positively correlated with *Enterococcus, Klebsiella, Streptococcus, Lactobacillus*, and proinflammatory cytokines. The mucosal expression of the BA membrane receptor TGR5 was significantly elevated in UC patients. Additionally, BA nuclear receptor VDR expression in colonic mucosal specimens was significantly decreased in UC patients. Based on these findings, we concluded that dysregulation of the gut microbiota and altered constitution of fecal BAs may participate in regulating inflammatory responses *via* the BA receptors TGR5 and VDR.

For demographics, 32 UC patients (17 males and 15 females; median age 37.0 years, IQR: 32.00-49.75) were enrolled in this study. Similar to previous studies, no sex predominance existed in UC, and the peak age of disease onset was between ages 30 years and 40 years[37]. In order to prevent initiation of medical treatment from changing the composition of the intestinal flora of UC patients, we collected stool samples as soon as possible within 1 d of UC patients' visit to ensure that the clinical symptoms were significant at the study entry. Except for five patients who took mesalazine for a short period of time, the remaining active (relapse) patients included in our study did not receive any treatment before collecting stool and serum samples. Although the time of active disease is not specified, the Mayo score of disease activity of the enrolled patients was required to be 4-12.

Gut microbes were demonstrated to be an essential factor in intestinal inflammation in UC. It has been consistently shown that there is a decrease in biodiversity and species richness in UC[38]. Changes in the composition of the gut microbiota led to metabolite alterations that are likely to have a role in UC pathogenesis[39]. The intestinal microbiota converts ingested food or host products into metabolites that target either the intestinal microbial population or host cells. Hence, the presence of metabolites depends on microbial metabolic activity[40,41]. It is estimated that more than 50% of metabolites found in fecal matter and urine are derived from or modified by the intestinal microbiota[42]. It is particularly noteworthy that the intestinal flora has an important influence on the composition of BA metabolites. The BAs in feces are mainly secondary BAs but also contain a small amount of primary BAs, trace conjugated BAs, and ursodeoxycholic acid (UDCA)[43]. The conversion of conjugated BAs to free BAs depends on the bile salt hydrolase that exists in the intestinal flora[44], which has been identified in *Bacteroides fragilis, Clostridium, Lactobacillus,* and *Bifidobacterium*. Thus, we infer that the imbalance of the intestinal flora affects the deconjugation of BAs, leading to an increase in the concentration of conjugated BAs. In agreement with these studies, we found that the concentrations of conjugated BAs such as TCA, TCDCA, and GCDCA in UC patients were significantly higher than those in HCs and negatively related to *Clostridium IV*, *Faecalibacterium*, *Ruminococcus*, and *Clostridium XlVb.*

A sequence of enzymatic reactions in the liver converts cholesterol to primary BAs in humans. The intestinal microbiota converts primary BAs to secondary BAs by various reactions, including deconjugation, dehydroxylation, esterification, and desulfatation[29,45-47]. Dehydroxylation only occurs after deconjugation and is catalyzed by the Firmicutes phylum*,* including *Clostridium* and *Eubacterium*. Desulfatation driven by BA sulfatase is catalyzed by *Clostridium*, *Peptococcus*, *Fusobacterium*, and *Pseudomonas*[47,48]. Therefore, dysregulation of gut microbiota impairs the deconjugation, dehydroxylation, and desulfatation of BAs. As a result, patients with UC have increased secondary BAs and decreased primary BAs. In accordance with these studies, we also found that the concentrations of fecal secondary BAs such as LCA, DCA, GDCA, GLCA, and TLCA in UC patients were significantly lower than those in HCs and were positively correlated with *Butyricicoccus*, *Roseburia*, *Clostridium IV*, *Faecalibacterium*, and *Clostridium XlVb.*

Moreover, we demonstrated that altered constitution of fecal BAs may participate in regulating inflammatory responses *via* BA receptors. TGR5 is a BA reactive receptor expressed in various cell types and is widely distributed throughout the gastrointestinal tract[49]. Different types of BAs have different agonistic effects on TGR5: LCA > DCA > CDCA > UDCA > CA[50]. TGR5 also plays a role in inflammation, energy balance, and insulin signaling[51]. Studies have shown that TGR5 negatively regulates liver inflammation in mice by antagonizing NF-κB signaling. Compared with WT mice, mice with *TGR5* gene deficiency have significantly higher levels of serum inflammation markers after induction with LPS, but treating WT mice with TGR5 agonists can reduce inflammatory responses[52]. Nevertheless, TGR5 is increased in experimental colitis, and the mRNA expression of *TGR5* is upregulated in patients with Crohn’s disease[53,54]. The anti-inflammatory properties of TGR5 indicate that TGR5 activation may be beneficial to IBD, which might be a compensatory mechanism to counterbalance the vicious cycle of inflammation in IBD.

In addition, this study found that BA metabolites can regulate the immune response in a VDR-dependent fashion. The nuclear receptor VDR is highly expressed in the small intestine and colon and is an essential regulator of intestinal cell proliferation, barrier function, and immunity[55,56]. Evidence strongly supports a protective effect of VDR in UC, and the underlying mechanism may be that VDR can ameliorate intestinal inflammation by downregulating NF-ĸB signaling and activating autophagy[57,58]. In experimental models of colitis, *Vdr* whole-body knockout mice are known to develop severe colitis[59]. The secondary BA LCA, as a VDR ligand that is produced by *Clostridium* bacteria in the gut lumen, controls Th1 immune responses and suppresses the production of the Th1 cytokines IFNγ and TNFα by activating VDR[60]. *Vdr* knockout mice have lower *Clostridium* in the gut, illustrating the influence of crosstalk between the microbiome and VDR signaling in immunity[61]. Consistent with previous studies[62], the current study showed that the low expression of VDR in the intestine of patients with UC may be related to the imbalance of the flora and the decrease of secondary BAs such as DCA and LCA.

There were several limitations in this study. First, due to limited time and conditions, the sample size was relatively small in this study, and subgroup analysis of the microbiota composition and BA profiles with different disease activities and stages of UC patients has not been performed yet. Previous studies have shown that there are differences in the intestinal flora of UC patients during active and remission periods[63,64]. Longitudinal analyses revealed reduced temporal microbiota stability in UC, particularly in patients with changes in disease activity[65,66]. As the number of subjects increases, we will collect stool samples from a large population of patients with UC at different time points during periods of active and remission disease and rank the contribution of variables to microbiota composition and BA profiles. Second, our conclusions are based on observational research, and such cross-sectional studies do not provide information about the timing of dysbiosis relative to disease onset and, therefore, should be interpreted with caution particularly with regards to cause–effect relationships[39]. We will later conduct intervention studies and animal experiments to verify their relationship. Third, considering that the short-term modification of a diet can rapidly disturb the gut microbiota[67], all subjects were required to maintain their daily dietary habits before the collection of the stool samples. However, dietary constituents have been shown to affect the inflammatory status, in great part mediated through the modulation of the microbiota[68,69], so it is better to supply a standardized diet for subjects. The standardized diet minimizes diet-induced deviations in the gut microbiota and BA metabolites, but masks the gut microbiota under usual dietary habits. Therefore, the measures of gut microbiota and BAs before and after a standardized diet combined with a detailed assessment of the usual dietary habits of patients are necessary for a future study. Finally, since the nuclear FXR is mostly distributed in hepatocytes, the small intestine, and macrophages[50], this study did not detect the expression of FXR in the colonic mucosa.

**CONCLUSION**

In conclusion, this study provides new evidence that fecal BAs are closely related to the gut microbiota and serum inflammatory cytokines. Dysregulation of the gut microbiota and altered constitution of fecal BAs may participate in regulating inflammatory responses *via* the BA receptors TGR5 and VDR. This study provides a preliminary exploration for possible involvement of the gut microbiota and BA metabolites in the inflammatory responses of UC in humans.

**ARTICLE HIGHLIGHTS**

***Research background***

The gut microbiota and its metabolites are involved in the pathogenesis of inflammatory bowel disease. Bile acid (BA) metabolites have recently drawn much attention in ulcerative colitis (UC). Animal studies have shown that secondary BAs participate in intestinal inflammatory responses *via* the BA receptors Takeda G-protein-coupled receptor 5 (TGR5) and vitamin D receptor (VDR). However, there are few studies about the quantitative analysis of fecal BAs and intestinal TGR5 and VDR expression in patients with UC. The relationship between BAs and inflammatory cytokines has not been investigated in UC patients. It was hypothesized that BA metabolites may play a role in the pathogenesis of UC.

***Research motivation***

The main topics of this study included clinical assessments, screening different key gut microbiota and BAs, examining BA receptor expression in UC patients and healthy controls (HCs), performing correlation analyses between these parameters, and clarifying whether there were similar mechanisms to those of animal studies in UC patients. The findings suggested a mechanism by which the gut microbiota and BAs may participate in the pathophysiology of UC and may provide new insights into the management of UC.

***Research objectives***

The aims of this study were to compare differences in the gut microbiota, fecal BAs, and BA receptor expression in the intestinal mucosa between UC patients and HVs and to analyze the relationship of BAs with the gut microbiota and inflammatory cytokines.

***Research methods***

The present study used 16S rDNA sequencing technology to detect the differences in the intestinal flora between UC patients and HCs. Fecal BAs were measured by targeted metabolomics approaches. Mucosal TGR5 and VDR expression was analyzed using immunohistochemistry, and serum inflammatory cytokine levels were detected by ELISA.

***Research results***

It was found that the diversity of gut microbes in UC patients was reduced compared with that in HCs. The concentrations of fecal secondary BAs such as lithochalic acid, deoxycholic acid, glycodeoxycholic acid, glycolithocholic acid, and taurolithocholic acid in UC patients were significantly lower than those in HCs and were positively correlated with *Butyricicoccus*, *Roseburia*, *Clostridium IV*, *Faecalibacterium*, and *Clostridium XlVb.* The concentrations of primary BAs such as taurocholic acid, cholic acid, taurochenodeoxycholic acid, and glycochenodeoxycholic acid in UC patients were significantly higher than those in HCs and positively correlated with *Enterococcus*, *Klebsiella*, *Streptococcus*, *Lactobacillus* and proinflammatory cytokines. The mucosal expression of TGR5 was significantly elevated in UC patients. VDR expression in colonic mucosal specimens was significantly decreased in UC patients.

***Research conclusions***

Fecal BAs are closely related to the gut microbiota and serum inflammatory cytokines. Dysregulation of the gut microbiota and altered constitution of fecal BAs may participate in regulating inflammatory responses *via* the BA receptors TGR5 and VDR. These findings not only contribute to the understanding of the role of the gut microbiota and metabolites in UC pathogenesis but also offer a valuable reference for future research and more effective therapies.

***Research perspectives***

This preliminary study investigated the changes in the fecal BA metabolite profile and analyzed the relationship between metabolites, the gut microbiota, and inflammation in patients with UC. In the future, we will focus on the following aspects. First, due to limited time and conditions, the sample size was relatively small, which may impact the reliability of the conclusion. Second, we cannot draw causal inferences in this cross-sectional study. Therefore, conclusions need to be further verified by well-designed large-sample clinical studies and basic studies. Third, diet was not standardized during the study period. It is necessary to standardize diet in future studies to avoid the influence of diet on the intestinal flora and metabolites.

**ACKNOWLEDGEMENTS**

We thank Dr. Du SY and Dr. Liu F for enrollment of participants.

**REFERENCES**

1 **Ng SC**, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, Kaplan GG. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *Lancet* 2017; **390**: 2769-2778 [PMID: 29050646 DOI: 10.1016/S0140-6736(17)32448-0]

2 **Kaplan GG**, Ng SC. Understanding and Preventing the Global Increase of Inflammatory Bowel Disease. *Gastroenterology* 2017; **152**: 313-321.e2 [PMID: 27793607 DOI: 10.1053/j.gastro.2016.10.020]

3 **D'Haens GR**, Sartor RB, Silverberg MS, Petersson J, Rutgeerts P. Future directions in inflammatory bowel disease management. *J Crohns Colitis* 2014; **8**: 726-734 [PMID: 24742736 DOI: 10.1016/j.crohns.2014.02.025]

4 **Nikfar S**, Rahimi R, Rezaie A, Abdollahi M. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. *Dig Dis Sci* 2009; **54**: 1157-1170 [PMID: 18770034 DOI: 10.1007/s10620-008-0481-x]

5 **De Cassan C**, Fiorino G, Danese S. Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects? *Dig Dis* 2012; **30**: 368-375 [PMID: 22796798 DOI: 10.1159/000338128]

6 **Cohen BL**, Sachar DB. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. *BMJ* 2017; **357**: j2505 [PMID: 28630047 DOI: 10.1136/bmj.j2505]

7 **Nitzan O**, Elias M, Peretz A, Saliba W. Role of antibiotics for treatment of inflammatory bowel disease. *World J Gastroenterol* 2016; **22**: 1078-1087 [PMID: 26811648 DOI: 10.3748/wjg.v22.i3.1078]

8 **Derwa Y**, Gracie DJ, Hamlin PJ, Ford AC. Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. *Aliment Pharmacol Ther* 2017; **46**: 389-400 [PMID: 28653751 DOI: 10.1111/apt.14203]

9 **Zabana Y**, Rodríguez L, Lobatón T, Gordillo J, Montserrat A, Mena R, Beltrán B, Dotti M, Benitez O, Guardiola J, Domènech E, Garcia-Planella E, Calvet X, Piqueras M, Aceituno M, Fernández-Bañares F, Esteve M. Relevant Infections in Inflammatory Bowel Disease, and Their Relationship With Immunosuppressive Therapy and Their Effects on Disease Mortality. *J Crohns Colitis* 2019; **13**: 828-837 [PMID: 30668662 DOI: 10.1093/ecco-jcc/jjz013]

10 **Baumgart DC**, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. *Lancet* 2007; **369**: 1641-1657 [PMID: 17499606 DOI: 10.1016/S0140-6736(07)60751-X]

11 **Ho GT**, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. *Aliment Pharmacol Ther* 2006; **24**: 319-330 [PMID: 16842459 DOI: 10.1111/j.1365-2036.2006.02974.x]

12 **Li J**, Wang F, Zhang HJ, Sheng JQ, Yan WF, Ma MX, Fan RY, Gu F, Li CF, Chen DF, Zheng P, Gu YP, Cao Q, Yang H, Qian JM, Hu PJ, Xia B. Corticosteroid therapy in ulcerative colitis: Clinical response and predictors. *World J Gastroenterol* 2015; **21**: 3005-3015 [PMID: 25780299 DOI: 10.3748/wjg.v21.i10.3005]

13 **Clarke WT**, Feuerstein JD. Colorectal cancer surveillance in inflammatory bowel disease: Practice guidelines and recent developments. *World J Gastroenterol* 2019; **25**: 4148-4157 [PMID: 31435169 DOI: 10.3748/wjg.v25.i30.4148]

14 **Magro F**, Rodrigues A, Vieira AI, Portela F, Cremers I, Cotter J, Correia L, Duarte MA, Tavares ML, Lago P, Ministro P, Peixe P, Lopes S, Garcia EB. Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts. *Inflamm Bowel Dis* 2012; **18**: 573-583 [PMID: 21793126 DOI: 10.1002/ibd.21815]

15 **Glassner KL**, Abraham BP, Quigley EMM. The microbiome and inflammatory bowel disease. *J Allergy Clin Immunol* 2020; **145**: 16-27 [PMID: 31910984 DOI: 10.1016/j.jaci.2019.11.003]

16 **Qin J**, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J; MetaHIT Consortium, Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* 2010; **464**: 59-65 [PMID: 20203603 DOI: 10.1038/nature08821]

17 **Ley RE**, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. *Cell* 2006; **124**: 837-848 [PMID: 16497592 DOI: 10.1016/j.cell.2006.02.017]

18 **Wong JM**, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. *J Clin Gastroenterol* 2006; **40**: 235-243 [PMID: 16633129 DOI: 10.1097/00004836-200603000-00015]

19 **Buffie CG**, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, Littmann E, van den Brink MR, Jenq RR, Taur Y, Sander C, Cross JR, Toussaint NC, Xavier JB, Pamer EG. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. *Nature* 2015; **517**: 205-208 [PMID: 25337874 DOI: 10.1038/nature13828]

20 **Fulde M**, Hornef MW. Maturation of the enteric mucosal innate immune system during the postnatal period. *Immunol Rev* 2014; **260**: 21-34 [PMID: 24942679 DOI: 10.1111/imr.12190]

21 **Ananthakrishnan AN**. Epidemiology and risk factors for IBD. *Nat Rev Gastroenterol Hepatol* 2015; **12**: 205-217 [PMID: 25732745 DOI: 10.1038/nrgastro.2015.34]

22 **Knox NC**, Forbes JD, Peterson CL, Van Domselaar G, Bernstein CN. The Gut Microbiome in Inflammatory Bowel Disease: Lessons Learned From Other Immune-Mediated Inflammatory Diseases. *Am J Gastroenterol* 2019; **114**: 1051-1070 [PMID: 31232832 DOI: 10.14309/ajg.0000000000000305]

23 **Sartor RB**, Wu GD. Roles for Intestinal Bacteria, Viruses, and Fungi in Pathogenesis of Inflammatory Bowel Diseases and Therapeutic Approaches. *Gastroenterology* 2017; **152**: 327-339.e4 [PMID: 27769810 DOI: 10.1053/j.gastro.2016.10.012]

24 **Lloyd-Price J**, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon TW, Andrews E, Ajami NJ, Bonham KS, Brislawn CJ, Casero D, Courtney H, Gonzalez A, Graeber TG, Hall AB, Lake K, Landers CJ, Mallick H, Plichta DR, Prasad M, Rahnavard G, Sauk J, Shungin D, Vázquez-Baeza Y, White RA 3rd; IBDMDB Investigators, Braun J, Denson LA, Jansson JK, Knight R, Kugathasan S, McGovern DPB, Petrosino JF, Stappenbeck TS, Winter HS, Clish CB, Franzosa EA, Vlamakis H, Xavier RJ, Huttenhower C. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. *Nature* 2019; **569**: 655-662 [PMID: 31142855 DOI: 10.1038/s41586-019-1237-9]

25 **Franzosa EA**, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S, Vatanen T, Hall AB, Mallick H, McIver LJ, Sauk JS, Wilson RG, Stevens BW, Scott JM, Pierce K, Deik AA, Bullock K, Imhann F, Porter JA, Zhernakova A, Fu J, Weersma RK, Wijmenga C, Clish CB, Vlamakis H, Huttenhower C, Xavier RJ. Gut microbiome structure and metabolic activity in inflammatory bowel disease. *Nat Microbiol* 2019; **4**: 293-305 [PMID: 30531976 DOI: 10.1038/s41564-018-0306-4]

26 **Duboc H**, Rajca S, Rainteau D, Benarous D, Maubert MA, Quervain E, Thomas G, Barbu V, Humbert L, Despras G, Bridonneau C, Dumetz F, Grill JP, Masliah J, Beaugerie L, Cosnes J, Chazouillères O, Poupon R, Wolf C, Mallet JM, Langella P, Trugnan G, Sokol H, Seksik P. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. *Gut* 2013; **62**: 531-539 [PMID: 22993202 DOI: 10.1136/gutjnl-2012-302578]

27 **Martinot E**, Sèdes L, Baptissart M, Lobaccaro JM, Caira F, Beaudoin C, Volle DH. Bile acids and their receptors. *Mol Aspects Med* 2017; **56**: 2-9 [PMID: 28153453 DOI: 10.1016/j.mam.2017.01.006]

28 **Lieu T**, Jayaweera G, Bunnett NW. GPBA: a GPCR for bile acids and an emerging therapeutic target for disorders of digestion and sensation. *Br J Pharmacol* 2014; **171**: 1156-1166 [PMID: 24111923 DOI: 10.1111/bph.12426]

29 **Wahlström A**, Sayin SI, Marschall HU, Bäckhed F. Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. *Cell Metab* 2016; **24**: 41-50 [PMID: 27320064 DOI: 10.1016/j.cmet.2016.05.005]

30 **Kolho KL**, Pessia A, Jaakkola T, de Vos WM, Velagapudi V. Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. *J Crohns Colitis* 2017; **11**: 321-334 [PMID: 27609529 DOI: 10.1093/ecco-jcc/jjw158]

31 **Bjerrum JT**, Wang Y, Hao F, Coskun M, Ludwig C, Günther U, Nielsen OH. Metabonomics of human fecal extracts characterize ulcerative colitis, Crohn's disease and healthy individuals. *Metabolomics* 2015; **11**: 122-133 [PMID: 25598765 DOI: 10.1007/s11306-014-0677-3]

32 **Zhang YL**, Cai LT, Qi JY, Lin YZ, Dai YC, Jiao N, Chen YL, Zheng L, Wang BB, Zhu LX, Tang ZP, Zhu RX. Gut microbiota contributes to the distinction between two traditional Chinese medicine syndromes of ulcerative colitis. *World J Gastroenterol* 2019; **25**: 3242-3255 [PMID: 31333315 DOI: 10.3748/wjg.v25.i25.3242]

33 **Dignass A**, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. *J Crohns Colitis* 2012; **6**: 965-990 [PMID: 23040452 DOI: 10.1016/j.crohns.2012.09.003]

34 **Satsangi J**, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. *Gut* 2006; **55**: 749-753 [PMID: 16698746 DOI: 10.1136/gut.2005.082909]

35 **Xie G**, Wang X, Jiang R, Zhao A, Yan J, Zheng X, Huang F, Liu X, Panee J, Rajani C, Yao C, Yu H, Jia W, Sun B, Liu P, Jia W. Dysregulated bile acid signaling contributes to the neurological impairment in murine models of acute and chronic liver failure. *EBioMedicine* 2018; **37**: 294-306 [PMID: 30344125 DOI: 10.1016/j.ebiom.2018.10.030]

36 **Xie G**, Zhong W, Li H, Li Q, Qiu Y, Zheng X, Chen H, Zhao X, Zhang S, Zhou Z, Zeisel SH, Jia W. Alteration of bile acid metabolism in the rat induced by chronic ethanol consumption. *FASEB J* 2013; **27**: 3583-3593 [PMID: 23709616 DOI: 10.1096/fj.13-231860]

37 **Cosnes J**, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. *Gastroenterology* 2011; **140**: 1785-1794 [PMID: 21530745 DOI: 10.1053/j.gastro.2011.01.055]

38 **Zuo T**, Ng SC. The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory Bowel Disease. *Front Microbiol* 2018; **9**: 2247 [PMID: 30319571 DOI: 10.3389/fmicb.2018.02247]

39 **Ni J**, Wu GD, Albenberg L, Tomov VT. Gut microbiota and IBD: causation or correlation? *Nat Rev Gastroenterol Hepatol* 2017; **14**: 573-584 [PMID: 28743984 DOI: 10.1038/nrgastro.2017.88]

40 **Krishnan S**, Ding Y, Saedi N, Choi M, Sridharan GV, Sherr DH, Yarmush ML, Alaniz RC, Jayaraman A, Lee K. Gut Microbiota-Derived Tryptophan Metabolites Modulate Inflammatory Response in Hepatocytes and Macrophages. *Cell Rep* 2018; **23**: 1099-1111 [PMID: 29694888 DOI: 10.1016/j.celrep.2018.03.109]

41 **Levy M**, Thaiss CA, Elinav E. Metabolites: messengers between the microbiota and the immune system. *Genes Dev* 2016; **30**: 1589-1597 [PMID: 27474437 DOI: 10.1101/gad.284091.116]

42 **Zheng X**, Xie G, Zhao A, Zhao L, Yao C, Chiu NH, Zhou Z, Bao Y, Jia W, Nicholson JK, Jia W. The footprints of gut microbial-mammalian co-metabolism. *J Proteome Res* 2011; **10**: 5512-5522 [PMID: 21970572 DOI: 10.1021/pr2007945]

43 **Bajor A**, Gillberg PG, Abrahamsson H. Bile acids: short and long term effects in the intestine. *Scand J Gastroenterol* 2010; **45**: 645-664 [PMID: 20334475 DOI: 10.3109/00365521003702734]

44 **Long SL**, Gahan CGM, Joyce SA. Interactions between gut bacteria and bile in health and disease. *Mol Aspects Med* 2017; **56**: 54-65 [PMID: 28602676 DOI: 10.1016/j.mam.2017.06.002]

45 **Gérard P**. Metabolism of cholesterol and bile acids by the gut microbiota. *Pathogens* 2013; **3**: 14-24 [PMID: 25437605 DOI: 10.3390/pathogens3010014]

46 **Chen ML**, Takeda K, Sundrud MS. Emerging roles of bile acids in mucosal immunity and inflammation. *Mucosal Immunol* 2019; **12**: 851-861 [PMID: 30952999 DOI: 10.1038/s41385-019-0162-4]

47 **Sittipo P**, Shim JW, Lee YK. Microbial Metabolites Determine Host Health and the Status of Some Diseases. *Int J Mol Sci* 2019; **20** [PMID: 31653062 DOI: 10.3390/ijms20215296]

48 **Lavelle A**, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. *Nat Rev Gastroenterol Hepatol* 2020; **17**: 223-237 [PMID: 32076145 DOI: 10.1038/s41575-019-0258-z]

49 **Kawamata Y**, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, Fukusumi S, Habata Y, Itoh T, Shintani Y, Hinuma S, Fujisawa Y, Fujino M. A G protein-coupled receptor responsive to bile acids. *J Biol Chem* 2003; **278**: 9435-9440 [PMID: 12524422 DOI: 10.1074/jbc.M209706200]

50 **Fiorucci S**, Distrutti E. The Pharmacology of Bile Acids and Their Receptors. *Handb Exp Pharmacol* 2019; **256**: 3-18 [PMID: 31201555 DOI: 10.1007/164\_2019\_238]

51 **Duboc H**, Taché Y, Hofmann AF. The bile acid TGR5 membrane receptor: from basic research to clinical application. *Dig Liver Dis* 2014; **46**: 302-312 [PMID: 24411485 DOI: 10.1016/j.dld.2013.10.021]

52 **Wang YD**, Chen WD, Yu D, Forman BM, Huang W. The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor κ light-chain enhancer of activated B cells (NF-κB) in mice. *Hepatology* 2011; **54**: 1421-1432 [PMID: 21735468 DOI: 10.1002/hep.24525]

53 **Cipriani S**, Mencarelli A, Chini MG, Distrutti E, Renga B, Bifulco G, Baldelli F, Donini A, Fiorucci S. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. *PLoS One* 2011; **6**: e25637 [PMID: 22046243 DOI: 10.1371/journal.pone.0025637]

54 **Yoneno K**, Hisamatsu T, Shimamura K, Kamada N, Ichikawa R, Kitazume MT, Mori M, Uo M, Namikawa Y, Matsuoka K, Sato T, Koganei K, Sugita A, Kanai T, Hibi T. TGR5 signalling inhibits the production of pro-inflammatory cytokines by *in vitro* differentiated inflammatory and intestinal macrophages in Crohn's disease. *Immunology* 2013; **139**: 19-29 [PMID: 23566200 DOI: 10.1111/imm.12045]

55 **Wu S**, Liao AP, Xia Y, Li YC, Li JD, Sartor RB, Sun J. Vitamin D receptor negatively regulates bacterial-stimulated NF-kappaB activity in intestine. *Am J Pathol* 2010; **177**: 686-697 [PMID: 20566739 DOI: 10.2353/ajpath.2010.090998]

56 **Barbáchano A**, Fernández-Barral A, Ferrer-Mayorga G, Costales-Carrera A, Larriba MJ, Muñoz A. The endocrine vitamin D system in the gut. *Mol Cell Endocrinol* 2017; **453**: 79-87 [PMID: 27913273 DOI: 10.1016/j.mce.2016.11.028]

57 **Wu S**, Zhang YG, Lu R, Xia Y, Zhou D, Petrof EO, Claud EC, Chen D, Chang EB, Carmeliet G, Sun J. Intestinal epithelial vitamin D receptor deletion leads to defective autophagy in colitis. *Gut* 2015; **64**: 1082-1094 [PMID: 25080448 DOI: 10.1136/gutjnl-2014-307436]

58 **Chen Y**, Zhang J, Ge X, Du J, Deb DK, Li YC. Vitamin D receptor inhibits nuclear factor κB activation by interacting with IκB kinase β protein. *J Biol Chem* 2013; **288**: 19450-19458 [PMID: 23671281 DOI: 10.1074/jbc.M113.467670]

59 **Kong J**, Zhang Z, Musch MW, Ning G, Sun J, Hart J, Bissonnette M, Li YC. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. *Am J Physiol Gastrointest Liver Physiol* 2008; **294**: G208-G216 [PMID: 17962355 DOI: 10.1152/ajpgi.00398.2007]

60 **Pols TWH**, Puchner T, Korkmaz HI, Vos M, Soeters MR, de Vries CJM. Lithocholic acid controls adaptive immune responses by inhibition of Th1 activation through the Vitamin D receptor. *PLoS One* 2017; **12**: e0176715 [PMID: 28493883 DOI: 10.1371/journal.pone.0176715]

61 **Jin D**, Wu S, Zhang YG, Lu R, Xia Y, Dong H, Sun J. Lack of Vitamin D Receptor Causes Dysbiosis and Changes the Functions of the Murine Intestinal Microbiome. *Clin Ther* 2015; **37**: 996-1009.e7 [PMID: 26046242 DOI: 10.1016/j.clinthera.2015.04.004]

62 **Liu W**, Chen Y, Golan MA, Annunziata ML, Du J, Dougherty U, Kong J, Musch M, Huang Y, Pekow J, Zheng C, Bissonnette M, Hanauer SB, Li YC. Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. *J Clin Invest* 2013; **123**: 3983-3996 [PMID: 23945234 DOI: 10.1172/JCI65842]

63 **Prosberg M**, Bendtsen F, Vind I, Petersen AM, Gluud LL. The association between the gut microbiota and the inflammatory bowel disease activity: a systematic review and meta-analysis. *Scand J Gastroenterol* 2016; **51**: 1407-1415 [PMID: 27687331 DOI: 10.1080/00365521.2016.1216587]

64 **Schirmer M**, Denson L, Vlamakis H, Franzosa EA, Thomas S, Gotman NM, Rufo P, Baker SS, Sauer C, Markowitz J, Pfefferkorn M, Oliva-Hemker M, Rosh J, Otley A, Boyle B, Mack D, Baldassano R, Keljo D, LeLeiko N, Heyman M, Griffiths A, Patel AS, Noe J, Kugathasan S, Walters T, Huttenhower C, Hyams J, Xavier RJ. Compositional and Temporal Changes in the Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to Disease Course. *Cell Host Microbe* 2018; **24**: 600-610.e4 [PMID: 30308161 DOI: 10.1016/j.chom.2018.09.009]

65 **Clooney AG**, Eckenberger J, Laserna-Mendieta E, Sexton KA, Bernstein MT, Vagianos K, Sargent M, Ryan FJ, Moran C, Sheehan D, Sleator RD, Targownik LE, Bernstein CN, Shanahan F, Claesson MJ. Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study. *Gut* 2021; **70**: 499-510 [PMID: 32536605 DOI: 10.1136/gutjnl-2020-321106]

66 **Halfvarson J**, Brislawn CJ, Lamendella R, Vázquez-Baeza Y, Walters WA, Bramer LM, D'Amato M, Bonfiglio F, McDonald D, Gonzalez A, McClure EE, Dunklebarger MF, Knight R, Jansson JK. Dynamics of the human gut microbiome in inflammatory bowel disease. *Nat Microbiol* 2017; **2**: 17004 [PMID: 28191884 DOI: 10.1038/nmicrobiol.2017.4]

67 **David LA**, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, Biddinger SB, Dutton RJ, Turnbaugh PJ. Diet rapidly and reproducibly alters the human gut microbiome. *Nature* 2014; **505**: 559-563 [PMID: 24336217 DOI: 10.1038/nature12820]

68 **Rapozo DC**, Bernardazzi C, de Souza HS. Diet and microbiota in inflammatory bowel disease: The gut in disharmony. *World J Gastroenterol* 2017; **23**: 2124-2140 [PMID: 28405140 DOI: 10.3748/wjg.v23.i12.2124]

69 **Kostovcikova K**, Coufal S, Galanova N, Fajstova A, Hudcovic T, Kostovcik M, Prochazkova P, Jiraskova Zakostelska Z, Cermakova M, Sediva B, Kuzma M, Tlaskalova-Hogenova H, Kverka M. Diet Rich in Animal Protein Promotes Pro-inflammatory Macrophage Response and Exacerbates Colitis in Mice. *Front Immunol* 2019; **10**: 919 [PMID: 31105710 DOI: 10.3389/fimmu.2019.00919]

**Footnotes**

**Institutional review board statement:** This study was approved by the Ethics Committee of China-Japan Friendship Hospital (No. 2019-K16).

**Informed consent statement:** All study participants provided written informed consent prior to study enrollment.

**Conflict-of-interest statement:** All authors report no conflicts of interest.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The authors have read the STROBE Statement, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** February 6, 2021

**First decision:** March 14, 2021

**Article in press:** May 25, 2021

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C, C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Boirivant M, Innocenti T **S-Editor:** Liu M **L-Editor:** Wang TQ **P-Editor:** Ma YJ


**Figure legends**



**Figure 1 Structural characteristics of intestinal microbes in the ulcerative colitis and control groups.** A: Among the 594 operational taxonomic units (OTUs) detected, a total of 317 OTUs were identified in the two groups, including 86 unique OTUs in the UC group and 191 unique OTUs in the control group. B: The dilution curve analysis based on the Chao1 index for community richness and the Shannon index for community diversity showed that the sequencing volume had covered all the microorganisms in the samples. C: The species accumulation curve shows that the sequencing sample size was sufficient, which reflected most of the microbial information in the sample. D: Principal coordinate analysis clearly differentiated the intestinal flora of the ulcerative colitis (UC) group from the control group. E: Chao community richness index or the Shannon and Simpson community α diversity indexes of the UC group were significantly lower than those of the control group. F: The community compositions of the intestinal microbes in the UC group and the control group were analyzed at the phylum and genus levels. UC: Ulcerative colitis; OTUs: Operational taxonomic units; PCoA: Principal coordinate analysis.




**Figure 2 Screening of different key microorganisms between the ulcerative colitis and control groups.** A: The Wilcoxon rank sum test of differential species between the two groups showed significant changes in the intestinal microbes between the ulcerative colitis and control groups; B: LEfSe analysis identified (threshold 2) the differential intestinal microbial communities between the two groups. UC: Ulcerative colitis; LDA: Linear discriminant analysis.




**Figure 3 Analysis of difference in fecal bile acids between the ulcerative colitis and control groups.** A: Principal component analysis was performed to evaluate the similarity of the fecal BAs of the two groups. Twenty-four BAs clearly distinguished the ulcerative colitis (UC) group from the control group; B: Heatmap showing the individual BA concentrations in the samples (log-transformed). Shades of red and blue represent high and low BA concentrations, respectively (see color scale); C-H: Fecal secondary BAs in UC patients, such as lithocholic acid, deoxycholic acid, glyco-deoxycholic acid, glyco-lithocholic acid, and tauro-lithocholate, were significantly lower than those in healthy controls; I and K-M: The primary BAs such as tauro-cholic acid, cholic acid, tauro-chenodeoxycholic acid, and glyco-chenodeoxycholic acid were significantly higher than those in healthy controls; J and N: The concentrations of chenodeoxycholic acid and glyco-cholic acid showed a tendency to increase in UC patients but the increases were not significant. UC: Ulcerative colitis; PCA: Principal component analysis; BAs: Bile acids; LCA: Lithocholic acid; DCA: Deoxycholic acid; GDCA: Glyco-deoxycholic acid; GLCA: Glyco-lithocholic acid; TLCA: Tauro-lithocholate; TCA: Tauro-cholic acid; CA: Cholic acid; TCDCA: Tauro-chenodeoxycholic acid; GCDCA: Glyco-chenodeoxycholic acid; CDCA: Chenodeoxycholic acid; GCA: Glyco-cholic acid.

****

**Figure 4 Correlations between fecal bile acids and intestinal microbes.** A heatmap of correlative assessments was made on the fecal bile acid metabolites and intestinal microbes (a*P* < 0.05, b*P* < 0.01). LCA: Lithocholic acid; DCA: Deoxycholic acid; GDCA: Glyco-deoxycholic acid; GLCA: Glyco-lithocholic acid; TLCA: Tauro-lithocholate; TDCA: Tauro-deoxycholic acid; UDCA: Ursodeoxycholic acid; TUDCA: Tauro-ursodeoxycholic acid; GUDCA: Glyco-ursodeoxycholic acid; TCA: Tauro-cholic acid; CA: Cholic acid; TCDCA: Tauro-chenodeoxycholic acid; GCDCA: Glyco-chenodeoxycholic acid; CDCA: Chenodeoxycholic acid; GCA: Glyco-cholic acid.



**Figure 5 Mucosal immunohistochemistry in patients with ulcerative colitis and healthy controls.** A and B: Takeda G protein-coupled receptor 5 (TGR5) immunoreactivity was mainly scattered in the epithelium in ulcerative colitis (UC) patients (scale bar = 20 μm); C and D: Vitamin D receptor (VDR) immunoreactivity was distributed in the epithelium and lamina propria in UC patients and healthy controls (Scale bar = 20 μm); E: The mean optical density of TGR5 in the colonic mucosa in UC patients was significantly higher than that in healthy controls (*P* = 0.0003); F: The mean optical density of VDR in the colonic mucosa decreased significantly in patients (*P* = 0.033). UC: Ulcerative colitis; TGR5: Takeda G protein-coupled receptor 5; VDR: Vitamin D receptor; MOD: Mean optical density.



**Figure 6 Serum inflammatory cytokine levels and correlations between fecal bile acids and serum inflammatory cytokines in all subjects.** A-E: The levels of IL-1α, IL-1β, TNF-α, IL-2, and IL-6 were significantly higher in UC patients (*P* < 0.0001); F: A heatmap of correlative assessments was made of the fecal bile acids and serum inflammatory cytokines ( a*P* < 0.05, b*P* < 0.01,c*P* < 0.001); G: A network diagram of correlative assessments was made on the fecal bile acid metabolites and serum inflammatory cytokines (purple nodes represent bile acid metabolites and orange nodes represent inflammatory cytokines; red lines represent positive correlations and blue lines represent negative correlations). a*P* < 0.05, b*P* < 0.01, c*P* < 0.001. LCA: Lithocholic acid; DCA: Deoxycholic acid; GDCA: Glyco-deoxycholic acid; GLCA: Glyco-lithocholic acid; TLCA: Tauro-lithocholate; TDCA: Tauro-deoxycholic acid; UDCA: Ursodeoxycholic acid; TUDCA: Tauro-ursodeoxycholic acid; GUDCA: Glyco-ursodeoxycholic acid; TCA: Tauro-cholic acid; CA: Cholic acid; TCDCA: Tauro-chenodeoxycholic acid; GCDCA: Glyco-chenodeoxycholic acid; CDCA: Chenodeoxycholic acid; GCA: Glyco-cholic acid.

**Table 1 Demographics and clinical characteristics of the study subjects**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Feature** | **UC patients** | **Controls** | | ***P* value** |
| *n* | 32 | 23 | | NA |
| Age (yr) | 37.0 (32.00, 49.75) | 32.0 (27.00, 51.00) | | 0.570 |
| Gender (male:female) | 17:15 | 13:10 | | 0.803 |
| Body mass index (kg/m2) | 21.85 ± 3.64 | 22.75 ± 2.95 | | 0.337 |
| Duration of disease (yr) | 2 (0.5, 8) | NA | | NA |
| Mayo score | 7.8 ± 1.9b | NA | | < 0.001 |
| BSFS score | 6.0 (6.0, 6.0)b | 4.0 (4.0, 4.0) | | < 0.001 |
| Inflammation location  Rectum  Left colon  Whole colon  Disease activity  Mild activity  Moderate activity  Severe activity | 9  11  12  5  25  2 | NA  NA  NA  NA  NA  NA  NA | NA  NA  NA  NA  NA  NA  NA | |

b*P* < 0.01 *vs* controls. The data are presented as the mean ± standard deviation or median (interquartile range). UC: Ulcerative colitis; BSFS: Bristol stool form scale; NA: Not applicable.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**